A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma
Latest Information Update: 20 Jan 2022
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms EUROSMART; SMART
- Sponsors AstraZeneca
- 06 Nov 2012 Planned number of patients changed from 8000 to 11500.
- 22 Sep 2010 Results of a subgroup analysis comparing outcomes in smokers versus nonsmokers presented at the 20th Annual Congress of the European Respiratory Society.
- 19 May 2010 Prospectively planned subgroup analysis assessing the effect of treatment on the fractional excretion of nitric oxide presented at the 106th International Conference of the American Thoracic Society.